论文部分内容阅读
日本治疗晚期肾病的特点是绝大多数用血液透析,而很少用尸体肾移植。1978年 Wing 等估计,全世界约有十万名血液透析病人,其中欧洲共同市场国家占30％、北美30％、日本20％、其余20％。同年日本尸体肾移植为100例,仅占世界尸体肾移植总数的0.4％,对比欧洲共同市场占60％、北美33％。日本现有53000人血液透析,其中一万多人每年要作血液透析,而肾移植每年不到100例。
Japan’s treatment of end-stage renal disease is characterized by the vast majority of hemodialysis, and cadaveric kidney transplantation is rarely used. In 1978 Wing et al estimated that there are approximately 100,000 hemodialysis patients worldwide, of which European Common Market countries account for 30%, North America 30%, Japan 20%, and the remaining 20%. In the same year, there were 100 cadaveric kidney transplants in Japan, which accounted for only 0.4% of the total number of kidney transplants in the world, compared with 60% in the European Common Market and 33% in North America. There are currently 53,000 people in Japan who have hemodialysis, of whom more than 10,000 have hemodialysis every year, and fewer than 100 kidney transplants occur each year.